Does the media prefer PURR or ACAD?

In the previous week, ACADIA Pharmaceuticals had 8 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 10 mentions for ACADIA Pharmaceuticals and 2 mentions for Hyperliquid Strategies. ACADIA Pharmaceuticals' average media sentiment score of 1.12 beat Hyperliquid Strategies' score of 1.08 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperliquid Strategies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is TNGX or PURR more profitable?

Tango Therapeutics' return on equity of -41.54% beat Hyperliquid Strategies' return on equity. Company Net Margins Return on Equity Return on Assets Tango Therapeutics N/A -41.54% -33.44% Hyperliquid Strategies N/A -56.04% -52.22%

Does the media favor TNGX or PURR?

In the previous week, Tango Therapeutics had 5 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 7 mentions for Tango Therapeutics and 2 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 1.08 beat Tango Therapeutics' score of 0.85 indicating that Hyperliquid Strategies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hyperliquid Strategies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NAMS or PURR?

In the previous week, NewAmsterdam Pharma and NewAmsterdam Pharma both had 2 articles in the media. Hyperliquid Strategies' average media sentiment score of 1.08 beat NewAmsterdam Pharma's score of 1.01 indicating that Hyperliquid Strategies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hyperliquid Strategies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PURR or DNLI more profitable?

Denali Therapeutics' return on equity of -52.20% beat Hyperliquid Strategies' return on equity. Company Net Margins Return on Equity Return on Assets Hyperliquid Strategies N/A -56.04% -52.22% Denali Therapeutics N/A -52.20% -43.86%

Does the media refer more to PURR or DNLI?

In the previous week, Denali Therapeutics had 6 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 8 mentions for Denali Therapeutics and 2 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 1.08 beat Denali Therapeutics' score of 0.76 indicating that Hyperliquid Strategies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperliquid Strategies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GPCR or PURR more profitable?

Structure Therapeutics' return on equity of -24.91% beat Hyperliquid Strategies' return on equity. Company Net Margins Return on Equity Return on Assets Structure Therapeutics N/A -24.91% -23.67% Hyperliquid Strategies N/A -56.04% -52.22%

Does the media refer more to GPCR or PURR?

In the previous week, Structure Therapeutics and Structure Therapeutics both had 2 articles in the media. Structure Therapeutics' average media sentiment score of 1.61 beat Hyperliquid Strategies' score of 1.08 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Hyperliquid Strategies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Hyperliquid Strategies (PURR) Competitors

$6.78 -0.83 (-10.91%)

Closing price 07/16/2026 04:00 PM Eastern

Extended Trading

$6.54 -0.24 (-3.47%)

As of 07/16/2026 07:59 PM Eastern

Compare

PURR vs. ACAD, TNGX, NAMS, DNLI, and GPCR

Should you buy Hyperliquid Strategies stock or one of its competitors? MarketBeat compares Hyperliquid Strategies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hyperliquid Strategies include ACADIA Pharmaceuticals (ACAD), Tango Therapeutics (TNGX), NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.

How does Hyperliquid Strategies compare to ACADIA Pharmaceuticals?

Hyperliquid Strategies (NASDAQ:PURR) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Hyperliquid Strategies currently has a consensus target price of $12.72, suggesting a potential upside of 87.56%. ACADIA Pharmaceuticals has a consensus target price of $32.94, suggesting a potential upside of 28.53%. Given Hyperliquid Strategies' higher probable upside, analysts clearly believe Hyperliquid Strategies is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Hyperliquid Strategies' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperliquid Strategies	N/A	-56.04%	-52.22%
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

In the previous week, ACADIA Pharmaceuticals had 8 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 10 mentions for ACADIA Pharmaceuticals and 2 mentions for Hyperliquid Strategies. ACADIA Pharmaceuticals' average media sentiment score of 1.12 beat Hyperliquid Strategies' score of 1.08 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperliquid Strategies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

9.5% of Hyperliquid Strategies shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 8.5% of Hyperliquid Strategies shares are owned by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

ACADIA Pharmaceuticals has higher revenue and earnings than Hyperliquid Strategies. Hyperliquid Strategies is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperliquid Strategies	$1M	979.37	-$16.01M	-$7.37	N/A
ACADIA Pharmaceuticals	$1.07B	4.10	$391M	$2.20	11.65

Hyperliquid Strategies has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

Summary

ACADIA Pharmaceuticals beats Hyperliquid Strategies on 13 of the 16 factors compared between the two stocks.

How does Hyperliquid Strategies compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Hyperliquid Strategies (NASDAQ:PURR) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

In the previous week, Tango Therapeutics had 5 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 7 mentions for Tango Therapeutics and 2 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 1.08 beat Tango Therapeutics' score of 0.85 indicating that Hyperliquid Strategies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hyperliquid Strategies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics' return on equity of -41.54% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-41.54%	-33.44%
Hyperliquid Strategies	N/A	-56.04%	-52.22%

Hyperliquid Strategies has lower revenue, but higher earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	64.09	-$101.59M	-$0.83	N/A
Hyperliquid Strategies	$1M	979.37	-$16.01M	-$7.37	N/A

Tango Therapeutics currently has a consensus price target of $41.85, indicating a potential upside of 51.40%. Hyperliquid Strategies has a consensus price target of $12.72, indicating a potential upside of 87.56%. Given Hyperliquid Strategies' higher probable upside, analysts plainly believe Hyperliquid Strategies is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 9.5% of Hyperliquid Strategies shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by company insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Tango Therapeutics has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market.

Summary

Tango Therapeutics beats Hyperliquid Strategies on 8 of the 15 factors compared between the two stocks.

How does Hyperliquid Strategies compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Hyperliquid Strategies (NASDAQ:PURR) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

NewAmsterdam Pharma presently has a consensus target price of $49.00, indicating a potential upside of 57.81%. Hyperliquid Strategies has a consensus target price of $12.72, indicating a potential upside of 87.56%. Given Hyperliquid Strategies' higher probable upside, analysts plainly believe Hyperliquid Strategies is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Hyperliquid Strategies has lower revenue, but higher earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	161.32	-$203.82M	-$1.79	N/A
Hyperliquid Strategies	$1M	979.37	-$16.01M	-$7.37	N/A

In the previous week, NewAmsterdam Pharma and NewAmsterdam Pharma both had 2 articles in the media. Hyperliquid Strategies' average media sentiment score of 1.08 beat NewAmsterdam Pharma's score of 1.01 indicating that Hyperliquid Strategies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hyperliquid Strategies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hyperliquid Strategies has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
Hyperliquid Strategies	N/A	-56.04%	-52.22%

NewAmsterdam Pharma has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market.

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 9.5% of Hyperliquid Strategies shares are owned by institutional investors. 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

NewAmsterdam Pharma beats Hyperliquid Strategies on 9 of the 16 factors compared between the two stocks.

How does Hyperliquid Strategies compare to Denali Therapeutics?

Hyperliquid Strategies (NASDAQ:PURR) and Denali Therapeutics (NASDAQ:DNLI) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

In the previous week, Denali Therapeutics had 6 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 8 mentions for Denali Therapeutics and 2 mentions for Hyperliquid Strategies. Hyperliquid Strategies' average media sentiment score of 1.08 beat Denali Therapeutics' score of 0.76 indicating that Hyperliquid Strategies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperliquid Strategies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

9.5% of Hyperliquid Strategies shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 8.5% of Hyperliquid Strategies shares are owned by company insiders. Comparatively, 12.5% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Hyperliquid Strategies has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperliquid Strategies	$1M	979.37	-$16.01M	-$7.37	N/A
Denali Therapeutics	$330.53M	10.91	-$512.54M	-$2.88	N/A

Denali Therapeutics' return on equity of -52.20% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperliquid Strategies	N/A	-56.04%	-52.22%
Denali Therapeutics	N/A	-52.20%	-43.86%

Hyperliquid Strategies has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

Hyperliquid Strategies currently has a consensus target price of $12.72, indicating a potential upside of 87.56%. Denali Therapeutics has a consensus target price of $35.08, indicating a potential upside of 54.35%. Given Hyperliquid Strategies' higher probable upside, research analysts clearly believe Hyperliquid Strategies is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

Denali Therapeutics beats Hyperliquid Strategies on 10 of the 16 factors compared between the two stocks.

How does Hyperliquid Strategies compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Hyperliquid Strategies (NASDAQ:PURR) are both pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

In the previous week, Structure Therapeutics and Structure Therapeutics both had 2 articles in the media. Structure Therapeutics' average media sentiment score of 1.61 beat Hyperliquid Strategies' score of 1.08 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Hyperliquid Strategies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 9.5% of Hyperliquid Strategies shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Structure Therapeutics presently has a consensus target price of $110.55, suggesting a potential upside of 140.16%. Hyperliquid Strategies has a consensus target price of $12.72, suggesting a potential upside of 87.56%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Structure Therapeutics is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Structure Therapeutics' return on equity of -24.91% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Hyperliquid Strategies	N/A	-56.04%	-52.22%

Structure Therapeutics has a beta of -1.5, suggesting that its stock price is 250% less volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market.

Hyperliquid Strategies has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Hyperliquid Strategies	$1M	979.37	-$16.01M	-$7.37	N/A

Summary

Structure Therapeutics beats Hyperliquid Strategies on 9 of the 14 factors compared between the two stocks.

Get Hyperliquid Strategies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PURR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PURR vs. The Competition

Export

Metric	Hyperliquid Strategies	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.10B	$3.14B	$5.09B	$12.67B
Dividend Yield	N/A	15.21%	34.29%	8.87%
P/E Ratio	-0.92	13.25	23.66	24.05
Price / Sales	979.37	2,719.23	132.64	112.08
Price / Cash	N/A	25.64	164.96	59.89
Price / Book	4.46	8.65	11.84	6.23
Net Income	-$16.01M	-$34.05M	$121.47M	$331.94M
7 Day Performance	-10.20%	-0.69%	-2.03%	-1.65%
1 Month Performance	-30.89%	-0.63%	-2.94%	-1.03%
1 Year Performance	N/A	10.94%	9.82%	17.10%

Hyperliquid Strategies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PURR Hyperliquid Strategies	2.304 of 5 stars	$6.78 -10.9%	$12.72 +87.6%	N/A	$1.10B	$1M	N/A	N/A	Positive News Gap Down
ACAD ACADIA Pharmaceuticals	4.8774 of 5 stars	$26.22 +0.1%	$32.94 +25.6%	+13.7%	$4.48B	$1.07B	11.89	510	Positive News
TNGX Tango Therapeutics	2.8051 of 5 stars	$31.14 +3.4%	$41.50 +33.3%	+335.3%	$4.46B	$62.38M	N/A	90	Analyst Forecast Gap Down
NAMS NewAmsterdam Pharma	3.095 of 5 stars	$36.69 -0.8%	$49.00 +33.6%	+48.4%	$4.28B	$22.50M	N/A	4	Positive News
DNLI Denali Therapeutics	3.064 of 5 stars	$26.38 +0.3%	$34.25 +29.8%	+52.9%	$4.20B	$330.53M	N/A	430	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PURR) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hyperliquid Strategies (PURR) Competitors

PURR vs. ACAD, TNGX, NAMS, DNLI, and GPCR

How does Hyperliquid Strategies compare to ACADIA Pharmaceuticals?

Summary

How does Hyperliquid Strategies compare to Tango Therapeutics?

Summary

How does Hyperliquid Strategies compare to NewAmsterdam Pharma?

Summary

How does Hyperliquid Strategies compare to Denali Therapeutics?

Summary

How does Hyperliquid Strategies compare to Structure Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PURR vs. The Competition

Hyperliquid Strategies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hyperliquid Strategies (PURR) Competitors

PURR vs. ACAD, TNGX, NAMS, DNLI, and GPCR

How does Hyperliquid Strategies compare to ACADIA Pharmaceuticals?

Do analysts recommend PURR or ACAD?

Is PURR or ACAD more profitable?

Does the media prefer PURR or ACAD?

Do institutionals and insiders hold more shares of PURR or ACAD?

Which has better earnings and valuation, PURR or ACAD?

Which has more volatility & risk, PURR or ACAD?

Summary

How does Hyperliquid Strategies compare to Tango Therapeutics?

Does the media favor TNGX or PURR?

Is TNGX or PURR more profitable?

Which has better earnings & valuation, TNGX or PURR?

Do analysts prefer TNGX or PURR?

Do institutionals and insiders hold more shares of TNGX or PURR?

Which has more volatility and risk, TNGX or PURR?

Summary

How does Hyperliquid Strategies compare to NewAmsterdam Pharma?

Do analysts recommend NAMS or PURR?

Which has preferable earnings and valuation, NAMS or PURR?

Does the media favor NAMS or PURR?

Is NAMS or PURR more profitable?

Which has more volatility & risk, NAMS or PURR?

Do institutionals and insiders have more ownership in NAMS or PURR?

Summary

How does Hyperliquid Strategies compare to Denali Therapeutics?

Does the media refer more to PURR or DNLI?

Do insiders & institutionals hold more shares of PURR or DNLI?

Which has higher earnings & valuation, PURR or DNLI?

Is PURR or DNLI more profitable?

Which has more volatility & risk, PURR or DNLI?

Do analysts rate PURR or DNLI?

Summary

How does Hyperliquid Strategies compare to Structure Therapeutics?

Does the media refer more to GPCR or PURR?

Do insiders & institutionals have more ownership in GPCR or PURR?

Do analysts rate GPCR or PURR?

Is GPCR or PURR more profitable?

Which has more risk and volatility, GPCR or PURR?

Which has preferable earnings and valuation, GPCR or PURR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PURR vs. The Competition

Hyperliquid Strategies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools